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Background: The extent of intratumoral mutational heterogeneity remains unclear in gliomas, the most common
primary brain tumors, especially with respect to point mutation. To address this, we applied single molecule
molecular inversion probes targeting 33 cancer genes to assay both point mutations and gene amplifications
within spatially distinct regions of 14 glial tumors.
Results: We find evidence of regional mutational heterogeneity in multiple tumors, including mutations in TP53
and RB1 in an anaplastic oligodendroglioma and amplifications in PDGFRA and KIT in two glioblastomas (GBMs).
Immunohistochemistry confirms heterogeneity of TP53 mutation and PDGFRA amplification. In all, 3 out of 14 glial
tumors surveyed have evidence for heterogeneity for clinically relevant mutations.
Conclusions: Our results underscore the need to sample multiple regions in GBM and other glial tumors when
devising personalized treatments based on genomic information, and furthermore demonstrate the importance of
measuring both point mutation and copy number alteration while investigating genetic heterogeneity within
cancer samples.Background
Regional heterogeneity of mutations has been observed
in a variety of tumor types [1,2]. This intratumoral het-
erogeneity has broad implications for the clinical man-
agement of cancer patients, especially in the current
paradigm of personalized medicine based on genomic
analysis of a single cancer biopsy. Within the context
of primary brain tumors, several groups have previ-
ously identified heterogeneity of gene amplifications in
genes EGFR and PDGFRA in glioblastoma multiforme
(GBM) using fluorescence in situ hybridization (FISH)
and array-comparative genomic hybridization on mul-
tiple regions within primary tumors [3,4]. Despite the* Correspondence: akash1@uw.edu; rosto@u.washington.edu; shendure@u.
washington.edu
1Department of Genome Sciences, University of Washington, Seattle, WA
98195, USA
3Department of Neurosurgery, University of Washington, Seattle, WA 98195,
USA
Full list of author information is available at the end of the article
© 2014 Kumar et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.dropping cost of DNA sequencing, however, the extent
of point mutational heterogeneity in brain tumors re-
mains limited to a single case of GBM [5]. This is in
part because the investigation of intratumoral hetero-
geneity requires both sampling and deep sequencing of
multiple regions in a tumor.
We recently developed a method to identify low fre-
quency mutations across known cancer genes [6] using
the single molecule molecular inversion probe (smMIP)
assay, which combines multiplex target capture with single
molecule tagging [6,7]. Here, we extend this technique to
detect gene amplifications and examine intratumoral het-
erogeneity by targeting 33 cancer genes across 62 spatial
sections of 14 glial tumors, including 10 grade IV gliomas
(all GBMs), three grade III gliomas (one each of ependy-
moma, astrocytoma, and anaplastic oligodendroglioma)
and one grade II astrocytoma. We detected intratumoral
heterogeneity in both point mutations and amplifications
of genes implicated as glioma tumor drivers and thera-
peutic targets.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Study design
To assess heterogeneity within gliomas, we dissected each
of 14 tumors into 3 to 5 regions per tumor (Figure 1A;
Table S1 in Additional file 1). We used the smMIP assay
on genomic DNA isolated from each region to identify
single nucleotide variants and high level copy amplifica-
tions (Figure 1B; Figure S1 in Additional file 1). smMIP
probes capture target sequence into covalently linked cir-
cular molecules after polymerase extension and ligation.
Following barcoding-PCR, sample pooling, sequencing,
deduplication and alignment, we identified high level am-
plifications and point mutations (Figure 1B,C; Figure S1 in
Additional file 1).Figure 1 Experimental approach. (A) Each tumor was divided into three
region was subdivided into four pieces for use in next generation sequenc
inversion probe method. Oligonucleotide probes were previously designed
sequence, molecular tag sequence as well as targeting arms homologous t
ligation, targeted sequence is captured within a circular molecule. Captured
samples are pooled and sequenced on the same lane. After tag-correction
to the human reference sequence to be used to identify copy number am
Additional details are provided in Figure S1 in Additional file 1. (C) Example
TP53 point mutation heterogeneity and EGFR amplification heterogeneity w
share either a point mutation or copy number alteration (in this case muta
mutation were not due to varying levels of tumor cellularity.Across the 14 tumors and 33 genes considered in this
analysis, we identified a total of 33 putative protein-
altering mutations (Tables S1 and S2 in Additional file 1).
Tumors had between zero and 16 putative protein-
altering mutations, with a median of two. TP53 was the
most commonly mutated gene, with mutations found in 8
out of 14 tumors (Figure 2A; Table S3 in Additional file 1).
One tumor, BI12, had many more candidate somatic
mutations than other tumors (n = 16 versus median n = 2
in other tumors). Mutations in this GBM were pre-
dominantly G > T (or C > A) transversions (8 of 16
total), possibly representing mutation from unrepaired
8-oxo-guanine damage. Most mutations were observed
across all tumor regions of BI12, consistent with a defectto five regions to assay intratumoral heterogeneity. Each individual
ing (NGS), histology, cell culture and xenotransplantation. (B) Molecular
against 33 cancer genes [6]. MIPs have a common backbone
o regions flanking targets of interest. After polymerase extension and
sequences are amplified in a barcoding-PCR reaction and multiple
(not shown), reads corresponding to each tumor region are mapped
plifications and point mutations specific to one region or another.
of comparisons: MIP captures of regions C and D can detect both
ithin a tumor. Tumors with mutational heterogeneity were required to
tion of PTEN) across all regions to ensure that differences in observed
Figure 2 Summary of heterogeneity observed across all samples. (A) Protein-altering mutations detected across all tumor regions. Genes
mutated twice in the same tumor region are not identified here but can be found within a table of all mutations (Table S3 in Additional file 1).
(B) High level gene amplifications detected by smMIP assay. Copy number was estimated by comparing all tumor samples against 12_X, a
universal control from BI12 (see Figure S2 in Additional file 1 for analysis using patient matched controls). ‘Amplification’ indicates genes
with coverage three-fold higher than median coverage across a sample. ‘High Amplification’ indicates genes with coverage six-fold higher
than median coverage across a sample. Region X refers to brain tissue grossly uninvolved by tumor. Our approach would miss any low-level
gene amplifications within these tumors.
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tumor.
To identify high level gene amplifications in tumors,
we compared read depth of smMIP-targeted regions in
each tumor against that of a control tissue. As smMIP
sequencing suggested that a subset of control tissues
were contaminated with tumor cells, we performed ana-
lyses using either patient-matched controls (Figure S2 in
Additional file 1) or a ‘universal’ control (Figure 2B). For
the latter we selected control tissue from tumor BI12, as
it appeared to have the least tumor contamination based
on allele fraction of known pathogenic point mutations,and restricted copy number analyses to targets with >30×
coverage in control tissue from BI12 as well as targets
whose GC percentage ranged from 30 to 60% (n = 885
capture probes). A careful review of discrepant calls when
using patient-matched versus a universal control indicated
that use of the universal control was more sensitive in
identifying bona fide amplification events (as confirmed
with Taqman assays) secondary to the contamination of a
subset of control tissues with tumor cells. After applying
our filters (see Materials and methods), a total of 21 genes
could be assayed in a total of 62 regions across 14 tumors
(Figure 2B).
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tive to the control tissue (from BI12). We used DNACopy
[8] to segment genes and obtain R, the mean ratio of
coverage relative to control for each gene. We estimated
the copy number for each gene by dividing R for each
gene by the median value of R across all genes for each tis-
sue. Genes with ratios above 3 were called as amplified.
Genes with ratios above 6 were called as highly amplified.
We did not measure deletion of genes using this method.
This process identified five tumors with gene amplifi-
cations, with three having one or more regions with a
highly amplified gene (Figure 2B). Three tumors had
amplification of both PDGFRA and KIT, and three tu-
mors had amplification of EGFR. We validated copy
number estimates for a subset of calls using a variety of
different methods, including Taqman quantitative PCR
(qPCR; across all tumors for EGFR and tumors BI05,
BI06 and BI15 for PDGFRA), as well as whole genome
sequencing (in tumor BI15 for EGFR). MIP copy num-
ber estimates of EGFR were highly correlated (R2 = 0.90)
with delta Ct obtained by Taqman qPCR when com-
pared across all 62 regions sequenced (Figure S3 in
Additional file 1). Additionally for five tumor regions of
BI15 that were subjected to light-whole genome se-
quencing, EGFR copy number estimates were consist-
ent between whole genome sequencing and smMIP
techniques (Supplementary methods and Figure S4 in
Additional file 1).
Tumors in which only a subset of regions possess an
amplification or point mutation with no other mutation
shared across regions can be the result of either mutationalFigure 3 Intratumoral heterogeneity of TP53 and RB1 determined fro
(A to E). Brain tissue grossly uninvolved by tumor was used as a control (X)
and RB1. This plot shows the allele balance of TP53 and RB1 mutations with
mutation in TP53, while regions D and E have a high allele fraction mutatio
region and also revealed that all regions shared a R132H mutation in IDH1heterogeneity within a tumor or varying levels of tumor
content between different tumor regions. As an example,
tumor BI15 was called as amplified for EGFR in two out
of five regions with no other somatic mutations/point mu-
tations detected across the tumor (Figures S5 and S6 in
Additional file 1). Upon close inspection of histologic
slides prepared from adjacent tissue, the observed differ-
ence in amplification was most likely due to lower tumor
cellularity within other regions of this tumor rather than
intratumoral genetic heterogeneity. This was also seen in
tumor BI04, where one region without detectable PDGFRA
amplification also had lower frequencies of a TP53 muta-
tion seen across all regions. For this reason, we chose to
restrict our interpretation of intratumoral heterogeneity to
tumors in which all regions also shared a point mutation
or gene amplification. Three tumors met these criteria
and are described below.
Spatial heterogeneity of TP53 and RB1 point mutations
One tumor exhibited clear spatial heterogeneity with re-
spect to point mutations within the 33 genes investigated
(Figure 3). BI09, an IDH1-mutant anaplastic oligodendro-
glioma, had a high allele fraction (>30% reads supporting
mutation) inactivating mutation (R248H) in TP53 in only
two regions of the tumor (A and B). This tumor had high
allele fraction mutations in RB1 exclusively in two other
regions (D and E) within the same tumor. Both TP53 and
RB1 mutations were present at trace levels (<1%) within
region C. As clinical workup indicated that BI09 had an
IDH1 mutation, we investigated all regions of this tumor
by Sanger sequencing and found that regions A to Em smMIP sequencing. Tumor BI09 was sectioned into five regions
. Each region was assayed for mutations in 33 genes, including TP53
in each tumor region. Regions A and B have a high allele fraction
n in RB1. Sanger results validated TP53 and RB1 mutations in each
(Figure S7 in Additional file 1).
Kumar et al. Genome Biology 2014, 15:530 Page 5 of 9
http://genomebiology.com/2014/15/12/530shared the IDH1 R132H mutation. Sanger sequencing
also validated the TP53 mutation in regions A and B as
well as the RB1 mutation in regions D and E (Figure S7
in Additional file 1). Immunohistochemistry of p53 and
IDH1-R132H expression on tissue adjacent to regions A
to E provided additional confirmatory evidence (Figure S8
in Additional file 1). These findings are consistent with an
IDH1-mutant tumor subsequently diverging to form sub-
clones with mutations in RB1 and TP53 [9,10]. A neuro-
pathologist (LFG-C) scored the grade and diagnosis for
each of these samples blinded to the mutation type. Inter-
estingly, the presence of TP53 mutation correlated with the
higher grade histology (Table S4 in Additional file 1).
The clinical significance is unknown but this serves as a
potential example of how genomic heterogeneity may
affect histology of a tumor.
Spatial heterogeneity of PDGFRA and KIT amplifications
Our smMIP technique detected amplification of PDGFRA,
KIT and EGFR within tumor BI05, an IDH1-wild type
glioblastoma. In this tumor EGFR amplification was
seen across all tumor regions, while amplification of
both PDGFRA and KIT was detected in two of five re-
gions (Figure 4A). As KIT is located near PDGFRA on
chromosome 4, shared amplification of these genes is
expected [11]. Taqman real-time PCR assays performed
in quadruplicate confirmed both the amplification in EGFR
and the amplification in PDGFRA across all assayed regionsFigure 4 Heterogeneity of PDGFRA amplification in BI05. (A) Copy num
(labeled) occurs in regions A and B with no amplification in regions C, D o
performed in quadruplicate. PDGFRA amplification occurs in regions A and
amplification in regions C, D and E. EGFR amplification occurs in all regions
PDGFRA amplification was also confirmed through immunohistochemistry
the mean +/- one standard deviation from quadruplicate values.(Figure 4B). Immunohistochemistry of PDGFRA and EGFR
on tissue adjacent to regions A to E provided additional
confirmatory evidence (Figure S9 in Additional file 1).
Similarly, we detected heterogeneity of PDGFRA amp-
lification within BI06, an IDH1-mutant glioblastoma. This
tumor had amplification of PDGFRA and KIT in region A
not detected within other regions (Figure 5A). Taqman
qPCR confirmed amplification of region A, mild amplifi-
cation in region B and no amplification in regions C, D
and E (Figure 5B). All other regions of this tumor had
somatic mutations in PTEN, such that reduced tumor cel-
lularity is an unlikely explanation for our observations.
Additional cases of heterogeneity are potential passenger
mutations
A missense mutation in KRAS was observed at moderate
allele fraction (10% of reads) in region D of the glioblast-
oma BI12 and was not detected in at least one other re-
gion (Table S3 in Additional file 1). As this mutation does
not occur within known mutation hotspots and is in a
tumor with signs of hypermutation (BI12), the clinical sig-
nificance of this heterogeneity remains unclear. Other
somatic point mutations are heterogeneous across an indi-
vidual tumor but occur within genes that have another,
ubiquitously distributed mutation. BI12 has missense mu-
tations in PTEN that are observed in regions A, B and C
and not in region D (Table S3 in Additional file 1). This
tumor also has another high allele fraction mutation inber estimates based on smMIP probe data. PDGFRA amplification
r E. (B) Results from Taqman qPCR targeting both PDGFRA and EGFR
B (between four- and eight-fold amplification) with no significant
of BI05, consistent with MIP sequencing results. Heterogeneity of
of regions A and E (Figure S9 in Additional file 1). Error bars represent
Figure 5 Heterogeneity of PDGFRA amplification in BI06. (A) Copy number estimates based on smMIP probe data. PDGFRA amplification
(labeled) occurs in region A with only mild amplification in region B and no clear detectable amplification in regions C, D or E. (B) Results from
Taqman qPCR targeting PDGFRA performed in quadruplicate. Region X refers to a region of brain tissue grossly uninvolved by tumor. PDGFRA
amplification occurs in region A (approximately four-fold amplification) with only mild amplification in regions B, C, D and E. Error bars represent
the mean +/- one standard deviation from quadruplicate values.
Kumar et al. Genome Biology 2014, 15:530 Page 6 of 9
http://genomebiology.com/2014/15/12/530this gene that is present across all regions of this tumor. A
similar scenario is seen in the astrocytoma BI08. Regions
D and E of this tumor have low allele fraction point muta-
tions in TP53, but all regions share another high allele
fraction mutation in the same gene. These results suggest
that the heterogeneously observed mutations observed are
more likely secondary passenger mutations that occurred
after PTEN and TP53 were inactivated in tumors BI12
and BI08, respectively (Table S3 in Additional file 1). An
alternative possibility is that tumors may contain distinct
subpopulations in which genes were inactivated by a dif-
ferent mutation.
Discussion
These results demonstrate that intratumoral spatial het-
erogeneity with respect to clinically relevant genes oc-
curs among multiple types of brain tumors, and spans
the mutational spectrum from copy number to point
mutations. Across a set of recurrently mutated cancer
genes (33 genes examined for point mutations, 21 genes
for amplifications), we observed heterogeneity for clinic-
ally relevant mutations in 3 of 14 (21%) glial tumors.
These include point mutations in TP53 and RB1 as well
as amplifications in PDGFRA/KIT. All cases of muta-
tional heterogeneity that we detected in a tumor occur
in adjacent regions, consistent with the hypothesis that
spatially distinct regions represent divergent subclones
of a single tumor.
Historically, in anaplastic oligodendroglioma with intact
1p, mutations in TP53 were found to stratify outcomes,with median survival of 71 versus 16 months in patients
with mutant versus wild-type TP53, respectively [12].
While not specifically applying to our patient in whom
1p/19q is deleted, our data demonstrating discrete differ-
ences in TP53 status from different regions within an indi-
vidual tumor nevertheless show the potential of genetic
heterogeneity to confound the assignment of prognostica-
tion based on the detection of specific molecular markers.
In addition, decision-making regarding the use of re-
ceptor tyrosine kinase inhibitors could be influenced by
the status of amplifications/mutations in PDGFRA. Our
finding of regional heterogeneity of PDGFRA within tu-
mors BI05 and BI06 confirms recent work by Sottoriva
et al. and others and suggests that a single biopsy may
not be sufficient to allow for informed application of tar-
geted therapies against these presumed oncogenic drivers
[3,4,13]. Clinical decision-making at recurrence will also
likely be impacted by regional heterogeneity. Nickel et al.
[5] compared mutations within a group of 10 genes from
2 regionally distinct samples of a single GBM at initial re-
section and 2 subsequent recurrences. No heterogeneity
was detected at initial resection but heterogeneity of
PIK3CA and PTEN mutation was detected at the first re-
currence, and heterogeneity of PIK3CA, TP53 and EGFR
mutation was detected at the second recurrence.
This study used tumor-adjacent brain to serve as a
‘control tissue’ to help identify somatic mutations. How-
ever, after extracting DNA and investigating mutations,
we observed that in several cases the grossly normal brain
tissue actually contained a large fraction of infiltrating
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cated the process of calling somatic point mutations (re-
quiring filtering against databases of germline variation)
and copy number (necessitating our use of a universal
control). While blood would be the most appropriate
material to use as a control we did not have institutional
review board approval to collect blood at the time these
experiments were conducted (subsequently modified to
allow for blood collection in the future).
In this study we were able to identify amplification of
only a subset of genes of interest, as some genes had too
few probes to accurately determine copy number. Our
study also did not detect genomic rearrangements and de-
letions such as the EGFR VIII deletion commonly found in
GBM. However, one can imagine expanding this assay to
consider amplifications and deletions with smMIPs by til-
ing probes at higher density and incorporating known SNP
positions to aid in identifying cases of loss of heterozygos-
ity. One could also capture additional glioma-relevant
genes like IDH1 and IDH2 by adding probes targeting
these genomic regions.
Our investigation focused on regional heterogeneity
within a tumor, instead of the microscopic heterogeneity
that is likely present within a given tumor biopsy. As we
performed the smMIP assay on DNA extracted from tis-
sue pieces that likely contained millions of cells, we would
likely miss cases of heterogeneity where only a small
population of cells within a biopsy contained a mutation
(such as an amplification). Use of techniques such as im-
munohistochemistry, FISH and, more recently, single cell
sequencing remain necessary to characterize the extent of
microscopic heterogeneity in tumors.
These results validate the smMIP approach as a scalable
and cost-effective platform for deep sequencing of cancer
genomes to examine subclonal variation. Despite deeply
sequencing multiple sections of 14 tumors, our survey re-
quired only one lane of sequencing on the Illumina HiSeq
because we focused on well-known gene targets of muta-
tion in cancer. In contrast to the technique used by a simi-
lar investigation [5], our method is also easily scaled and
amenable to automation with samples processed in 96-
well formats. This advantage in scalability enables one to
easily assay many more regions (tens to hundreds) per
tumor to obtain much finer scale pictures of intratumoral
heterogeneity, as we are likely underestimating its extent
even here by sampling of only a few regions. While our
study represents an improvement over previous studies,
analysis of greater number of genes in a greater number of
tumors will be necessary to determine rates of regional
heterogeneity in different driver mutations across GBMs.
Conclusions
We find multiple instances of regional heterogeneity in
clinically relevant cancer genes within malignant gliomasat the time of diagnosis. We also demonstrate a scalable
technique that can be used to efficiently characterize re-
gional genetic heterogeneity for both point mutations and
copy number alterations in tumors. Future challenges will
include how best to interpret cases of intratumoral hetero-
geneity and test its impact in the context of clinical trials
using targeted therapy approaches.
Materials and methods
Samples
Freshly resected brain tumor specimens from adult pa-
tients were obtained with informed consent as part of the
Genomics Big Idea pilot program (UW/FHCRC). Tissue,
patient demographics and final diagnosis were obtained in
accordance with protocols approved by the institutional
review board at the University of Washington. Tumors
were divided into three to five regions, depending on size.
Tissue from each region was then subdivided into four
pieces for use in next generation sequencing, histology,
cell culture and xenotransplantation (Figure 1). In 10
cases, brain grossly uninvolved by tumor was resected
to provide adequate surgical access and was utilized as a
source of germline or ‘control’ DNA to identify somatic
mutations (Table S1 in Additional file 1). These tissues
are referred to as regions “X” in this manuscript. For all
samples, DNA was isolated from snap-frozen tissue
pieces using the QIAGEN DNEasy Blood and Tissue kit
(Qiagen, Venlo, Netherlands).
Targeted capture and sequencing
The smMIP assay was used to genotype candidate genes.
Probes were previously designed by Hiatt et al. [6]
against 33 genes that are commonly mutated in cancer
(Table S2 in Additional file 1). Targeted capture and
PCR amplification were performed as previously de-
scribed, except that 200 ng of genomic DNA was used
for each sample instead of 500 ng [6]. After smMIP cap-
ture, amplified products were pooled and sequenced on
a single lane of the Illumina HiSeq 2000 platform with
paired 100-nucleotide reads and an 8- nucleotide index
read.
Primary analysis and variant calling
Initial analysis steps through to read mapping were per-
formed as previously described [6], except that instead
of constructing a consensus read from tagged smMIP
molecules, we chose one read per unique molecular tag
event at random for subsequent analysis.
Variants were called using SAMtools, and were filtered
for positions with phred base quality ≥30, ≥30× coverage
and the absence of a neighboring homopolymer run of
four bases or more (Table S2 in Additional file 1). To re-
move common polymorphisms and enrich for likely
somatic mutations, we imposed a number of additional
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with an allele balance of at least 5% within a sample, re-
moving variants present within a modified database of the
Exome Sequencing Project [14] and 1000 Genomes [15]
pilot project that had first been stripped of all COSMIC
variants, removing variants that were present at an allele
balance of at least 5% in two or more control samples.
Copy number analysis
We compared read depth of smMIP-targeted regions in
each tumor against that of the control tissue BI12 to
identify high level gene amplifications in tumors. We re-
stricted the copy number analysis to targets with greater
than 30× coverage in control tissue and a GC content
ranging from 30 to 60%. To reduce the number of po-
tential artifacts remaining, we removed from consider-
ation (for the purposes of copy number analysis only) 12
genes (AKT1, AKT2, CDK4, CDKN2A, FGFR3, HRAS,
KRAS, MYC, NRAS, SRC, STK11, and VHL) that had
fewer than 15 probes with sufficient coverage in the control
tissue (BI12).
After calculating the ratio of coverage for each probe
relative to control tissue from BI12, we used DNACopy
[8] to segment genes into discrete levels of coverage and
obtain R, the mean ratio of coverage relative to control
for each gene. We estimated the copy number for each
gene by dividing R for each gene by the median value of
R across all genes for each tissue. Genes with ratios above
3 were called as amplified and genes with ratios above 6
were called as highly amplified.
Sanger validation
DNA from five regions of tumor BI09 were subjected to
Sanger sequencing (Genewiz, South Plainfield, New Jersey,
USA) against positions within IDH1,TP53 and RB1.
Copy number validation
Tumors with regional heterogeneity in EGFR and PDGFRA
detected using smMIP sequencing were confirmed using
Taqman qPCR analysis. DNA from each region was an-
alyzed in quadruplicate using commercially available
probes against PDGFRA (assay ID: Hs02749151_cn;
Life Technologies, Waltham, Massachusetts, USA) and
EGFR (assay ID: Hs07526740_cn; Life Technologies).
Reference primers amplified a fragment from TERT
(number 4403316; Life Technologies). Finally, to compare
sensitivity of the smMIP approach, all regions from all tu-
mors were assayed in duplicate for EGFR copy number.
Immunohistochemistry and FISH
Immunohistochemistry for IDH1 and p53 was performed
on 4-micron paraffin sections using mouse anti-human
p53 clone (1:2,000 dilution; DAKO, Glostrup, Denmark)
and mouse anti-human IDH1 R132H (1:200 dilution;Dianova, Hamburg, Germany). All tumors were investi-
gated for IDH1 mutation by neuropathology, while only a
subset of tumors was investigated for p53 expression by
immunohistochemistry (Table S1 in Additional file 1).
Immunohistochemistry for EGFR and PDGFRA was per-
formed on 5- to 6-micron paraffin sections using mouse
anti-human EGFR, clone 2-18C9 (pharmDx kit, DAKO)
and rabbit anti-human PDGFRα, clone D1E1E (1:500 dilu-
tion; Cell Signaling, Danvers, Massachusetts, USA). Dual-
color EGFR FISH was performed using commercially
available probes (LSI EGFR SpectrumOrange/CEP 7
SpectrumGreen, number 32-191053; Abbott Molecular,
Chicago, Illinois, USA) with DAPI counterstain using
standard methods. Slides were imaged using an Olympus
DP72 digital camera mounted on a Nikon E400 micro-
scope. Fifty nuclei were scored for each region. EGFR
amplification was called if more than 10% of nuclei either
contained many EGFR signals or exhibited a EGFR:CEP7
ratio greater than 2. 1p19q deletion FISH was performed
using commercially available probes (number 04 N60-020,
Abbot Molecular) using standard methods.
Data availability
All sequence data from smMIP capture experiments
have been deposited in the NCBI Sequence Read Archive
(SRA) under accession number SRP049298.
Additional file
Additional file 1: Supplementary figures, tables and their
associated legends.
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